Simple and effective bacterial-based intratumoral cancer immunotherapy.

Christina S E CarrollErin R AndrewLaeeq MalikKathryn F ElliottMoira BrennanJames MeyerAlexander HintzeAndrew A AlmonteCassandra LappinPhilip MacPhersonKlaus-Martin SchulteJane E DahlstromRohit TamhaneTeresa NeemanElizabeth W HerbertMaurice OrangeDesmond YipRachel AllavenaAude M Fahrer

Published in: Journal for immunotherapy of cancer (2022)

Our data demonstrate that intratumoral injection of CFA has major antitumor effects in a proportion of treated animals and is safe for use in human cancer patients. Further trials in human cancer patients are therefore warranted. Our novel treatment provides a simple and inexpensive cancer immunotherapy, immediately applicable to a wide range of solid tumors, and is suitable to patients in developing countries and advanced care settings.

Keyphrases

endothelial cells
end stage renal disease
newly diagnosed
induced pluripotent stem cells
healthcare
ejection fraction
chronic kidney disease
pluripotent stem cells
peritoneal dialysis
quality improvement
pain management
combination therapy
smoking cessation
data analysis